In the wake of Cronos group (NASDAQ:CRON; TSXV:CRON) becoming the first Canadian licensed producer (LP) to offer its common stock in the Nasdaq Global Market, a selection of fellow LPs have since announced their intentions to also join premier US stock exchanges soon enough.

Bruce Linton, CEO of Canopy Growth (TSX:WEED) said during a public event in early March that his company was already preparing for a Nasdaq listing when it became involved with an investment deal from alcohol producer Constellation Brands (NYSE:STZ).

The Nasdaq listing for cannabis companies will require these companies do not hold assets in the US that involve any physical interaction with marijuana.

“The Nasdaq is doing a great job not allowing people to list who break federal laws and that’s a place where we should list in due course,” Linton said.

As reported by the Financial Post, Beacon Security analyst Vahan Ajamian wrote in a note that he expected the Canopy US listing to take place in the second quarter of the 2018 fiscal year.

Not to be left behind, Aurora Cannabis (TSX:ACB; OTC:ACBFF), which already lists on the OTCQX Best Market, announced it is also exploring the option to offer its stock on other exchanges.

“We’ll look at all exchanges, we’ll look at New York Stock Exchange,” Terry Booth, CEO of Aurora told Bloomberg.

Cronos trying to showcase legal cannabis market

After launching its stock on the Nasdaq, Mike Gornstein, CEO of Cronos said the entire industry is trying to raise awareness of the burgeoning legal cannabis industry.

“We did have a number of investors we’d speak to in the US that would ask ‘is it even legal to invest in a Canadian cannabis company?’ And by listing on the Nasdaq we are able to help that,” Gornstein told BNN.

Gornstein added part of the company’s motive behind launching on the Nasdaq relates to the possibility of entering the US market once it becomes federally legal and attracting American investors ahead of time.

Cronos officially launched its Nasdaq stock on March 6. Since then its share price has gone down 10.99 percent. At market close on Monday (March 12) market closure, Cronos finished at $8.79 signifying a 5.63 decrease and a $0.53 loss per share.

Investor Takeaway

Spearheaded by Cronos, the move to offer stock in the premier US exchanges offers a chance at legitimacy for the entire cannabis industry and–as repeatedly explained by executives–the type of investors available on these exchanges.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

US Election 2020 and Cannabis

Investing in cannabis? Read what experts have to say about cannabis and the US Election!

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.

Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .

Keep reading... Show less
  • On November 19 , the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally
  • On March 31, 2020 , the Company entered into an agreement with Tecnologico de Monterrey , the leading university in Mexico , to educate physicians across Latin America , in advance of the impending regulations in Mexico
  • To date, close to 550 LatAm physicians have obtained their diploma accrediting completion of Khiron’s medical education program
  • The Company plans to deploy its ZereniaTM medical cannabis clinics and telehealth strategy in Mexico , building on the success of its vertical integration strategy in Colombia
  • Expanding the Zerenia clinic strategy will build on the Company’s Colombia knowledge and proven distribution capabilities, with rapid telehealth service adoption and over 5,600 medical cannabis scripts filled to date
  • Mexico represents one of the largest potential markets for medical cannabis in the world and is anticipated to reach $1.2bn USD by 2028 (Prohibition Partners).
  • Company to release Q3 2020 financials and host webcast on Tuesday, December 1st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe welcomes the passing of adult-use cannabis legislation by the Mexican Senate, which moves the country closer to a legalized cannabis market, and towards provision for medical cannabis products.  Khiron has had a presence in Mexico since 2018 and has been working with doctors and medical institutions to develop a deep understanding of the market.

Keep reading... Show less

Recap of special management call includes upcoming corporate milestones and details of proposed combination with established beverage manufacturer

Emerging leader in infused cannabis beverages, BevCanna Enterprises Inc. (CSE:BEV, OTCQB:BVNNF, FSE:7BC) (“BevCanna” or the “Company”) is pleased to provide a recorded recap of the special management call held on Tuesday November 24, 2020. The call discussed upcoming corporate milestones and reviewed recent developments at the developer and manufacturer of cannabinoid‐infused beverages and consumer products for in‐house brands and white label clients.

Keep reading... Show less